Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akouos, Inc. stock logo
AKUS
Akouos
$13.29
$13.29
$2.32
$13.60
$490.88M-0.55344,411 shs440 shs
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
$44.15
$44.17
$16.02
$45.23
$913.91M1.03704,539 shs1.24 million shs
Atreca, Inc. stock logo
BCEL
Atreca
$0.09
$0.09
$0.05
$1.20
$3.57M1.034.61 million shsN/A
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
$19.00
$18.88
$8.82
$21.86
$794.77M0.881.36 million shsN/A
Organigram Global Inc. stock logo
OGI
Organigram Global
$1.32
-2.2%
$1.29
$0.85
$2.08
$180.82M1.37658,848 shs389,654 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akouos, Inc. stock logo
AKUS
Akouos
0.00%0.00%0.00%0.00%0.00%
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
0.00%0.00%0.00%0.00%0.00%
Atreca, Inc. stock logo
BCEL
Atreca
0.00%0.00%0.00%0.00%0.00%
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Organigram Global Inc. stock logo
OGI
Organigram Global
0.00%+5.47%+2.14%+29.81%-12.34%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akouos, Inc. stock logo
AKUS
Akouos
N/AN/AN/AN/AN/AN/AN/AN/A
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Atreca, Inc. stock logo
BCEL
Atreca
N/AN/AN/AN/AN/AN/AN/AN/A
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Organigram Global Inc. stock logo
OGI
Organigram Global
1.1566 of 5 stars
0.01.00.00.03.10.02.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akouos, Inc. stock logo
AKUS
Akouos
0.00
N/AN/AN/A
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
0.00
N/AN/AN/A
Atreca, Inc. stock logo
BCEL
Atreca
0.00
N/AN/AN/A
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
0.00
N/AN/AN/A
Organigram Global Inc. stock logo
OGI
Organigram Global
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akouos, Inc. stock logo
AKUS
Akouos
N/AN/AN/AN/A$4.90 per shareN/A
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
$40.58M22.52N/AN/A$9.11 per share4.85
Atreca, Inc. stock logo
BCEL
Atreca
N/AN/AN/AN/A$2.01 per shareN/A
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
$285.71M2.78N/AN/A$1.72 per share11.05
Organigram Global Inc. stock logo
OGI
Organigram Global
$117.47M1.51N/AN/A$2.07 per share0.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akouos, Inc. stock logo
AKUS
Akouos
-$86.67M-$2.62N/AN/AN/AN/A-45.09%-36.86%N/A
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
-$34.03M-$6.72N/AN/AN/A-228.51%-97.13%-46.89%N/A
Atreca, Inc. stock logo
BCEL
Atreca
-$97.16M-$2.50N/AN/AN/AN/A-157.90%-71.39%N/A
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
$221.82M-$1.48N/A9.84N/A-19.39%-77.48%-11.99%N/A
Organigram Global Inc. stock logo
OGI
Organigram Global
-$33.39M$0.1013.20N/AN/A8.05%-5.93%-4.39%8/12/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akouos, Inc. stock logo
AKUS
Akouos
N/AN/AN/AN/AN/A
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
N/AN/AN/AN/AN/A
Atreca, Inc. stock logo
BCEL
Atreca
N/AN/AN/AN/AN/A
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
N/AN/AN/AN/AN/A
Organigram Global Inc. stock logo
OGI
Organigram Global
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akouos, Inc. stock logo
AKUS
Akouos
N/A
17.30
17.30
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
N/A
6.32
6.23
Atreca, Inc. stock logo
BCEL
Atreca
N/A
1.58
1.58
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
3.12
4.22
2.52
Organigram Global Inc. stock logo
OGI
Organigram Global
N/A
3.42
1.90

Institutional Ownership

CompanyInstitutional Ownership
Akouos, Inc. stock logo
AKUS
Akouos
N/A
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
94.25%
Atreca, Inc. stock logo
BCEL
Atreca
37.47%
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
83.81%
Organigram Global Inc. stock logo
OGI
Organigram Global
34.63%

Insider Ownership

CompanyInsider Ownership
Akouos, Inc. stock logo
AKUS
Akouos
4.80%
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
6.90%
Atreca, Inc. stock logo
BCEL
Atreca
11.30%
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
6.20%
Organigram Global Inc. stock logo
OGI
Organigram Global
0.09%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akouos, Inc. stock logo
AKUS
Akouos
10336.94 million35.16 millionNot Optionable
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
13020.70 million19.27 millionOptionable
Atreca, Inc. stock logo
BCEL
Atreca
13039.62 million35.15 millionOptionable
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
34141.83 million39.19 millionOptionable
Organigram Global Inc. stock logo
OGI
Organigram Global
860133.94 million133.82 millionOptionable

Recent News About These Companies

OGI Organigram Global Inc. - Seeking Alpha
Organigram Global Inc. (OGI.TO)
Organigram acquires Collective Project for C$6.2M
Stocks in play: Organigram Global Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Akouos stock logo

Akouos NASDAQ:AKUS

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Albireo Pharma stock logo

Albireo Pharma NASDAQ:ALBO

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Atreca stock logo

Atreca NASDAQ:BCEL

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

Intercept Pharmaceuticals stock logo

Intercept Pharmaceuticals NASDAQ:ICPT

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..

Organigram Global stock logo

Organigram Global NASDAQ:OGI

$1.32 -0.03 (-2.22%)
Closing price 04:00 PM Eastern
Extended Trading
$1.33 +0.01 (+0.76%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.